SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE						ATTY. DOCKET NO. 8321-90			SERIAL NO.: Not Yet Assigned 09/773,830				
INFORMATION DISCLOSURE CITATION						APPLICANT: Ziwei Huang, et al							
						FILING D	bruary 1	GROUP Not Yet Assigned			gned		
				Ţ	J.S. PATENT DO	CUMEN	TS						
EXAMIN INITIAL			DOCUMENT DATE NUMBER		NAN			CLASS	SUBCLASS		FILING DATE (IF APPROPRIATE)		
lle		AA	5,846,933	12/8/1998	Korngold, et al.			514	11				
		AB				D C CITA		<u> </u>					
				FOI	REIGN PATENT I	DOCUM	EN15	T					
			DOCUMENT NO.	DATE	COUNT	TRY CLASS		SUB	CLASS TRAN YES		ISLATION NO		
	AC												
	AD				A							<u> </u>	
			OTHER DO	CUMENT	S (Including Autho	r, Title,	Date, Po	ertinent	Pages,	Etc.)	aca Inflomit	0.07	
Ste	Al	3	Protein-II (VMI	P-II) Reveals a	dy on the Anti-Human Im Fully Monomeric Protein	" Blocnem	isiry, voi.	30, pp. 44	24455 (15	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		ical	
ele AF		Society Zhou, et al: "A Novel Peptide Antagonist of CXCR4 Derived from the N-Terminus of Viral Chemokine vMIP-II" Biochemistry, Vol. 39, pp.3782-3787 (2000) American Chemical Society											
	A												
	A									· ·			
EXAMI	A A	L				ATE CON	SIDERED						
LAAVI		χ	1.			51	105/0	4					
EXAM	Mu NER	Initial	if citation consider	red, whether or	not citation is in conforman	ce with MPI	EP 609; Dr	aw line thro	ough citati	on			
if not in	confor	mance	and not considered	l. Include copy	of this form with next com	nunication t	o applicant	<u>. </u>					

Docket No: HUA01-NP007 U.S. Department of Commerce Eorm PTO - 1449 Serial No.: 09/773,830 Patent and Trademark Office (Magnified) Applicant: HUANG, Ziwei Filing Date: 01-Feb-2001 Information Disclosure Art No. uStatement by Applicant Examiner: tuse several Sheets if necessary) U.S. PATENT DOCUMENTS TRADEMA Filing Date Sub-Issue Exmr If Appropriate Patentee Class Class Patent Number Date Initial FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION Sub-Translation? Document Number Publn Exmr Class Class Yes No Date* Country or Patent Office Initial OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication**) Wells, T. N. C., Power, C. A., Lusti-Narasimhan, M., Hoogewerf, A. J., Cooke, R. M., Chung, C. W, Peitsch, M. C., and Proudfoot, A. E. I. "Selectivity and Antagonism of Chemokine Receptors." J. Leuk. Biol. 59: 53-60, 1996. Moore, P. S., Boshoff, C., Weiss, R.A., and Chang, Y. "Molecular Mimicry of Human Cytokine and Cytokine Response Pathway Genes by KSHV." Science 274: 1739-1744, 1996. Boshoff, C., Endo, Y., Collins, P. D., Takeuchi, Y., Reeves, J. D., Schweickart, V. L., Siani, M.A., 3 Sasaki, T., Williams, T. J., Gray, P. W., Moore, P. S., Chang, Y., and Weiss, R. A. "Angiogenic and HIV-Inhibitory Functions of KSHV-Encoded Chemokines." Science 278: 290-294, 1997. Kledal, T. N., Rosenkilde, M. M., Coulin, F., Simmons, G. Johnsen, A. H., Alouani, S., Power, C. A., Lüttichau, H. R., Gerstoft, J., Clapham, P. R., Clark-Lewis, I. Wells, T. N. C., and Schwartz, T. W. "A Broad-Spectrum Chemokine Anatagonist Encoded by Kaposi's Sarcoma-Associated Herpesvirus." Science 277: 1656-1659, 1997. Clark-Lewis, I., Kim, K. S., Rajarathnam, K., Gong, J. H., Dewald, B., Moser, B., Baggiolini, M., and Sykes, B. D. "Structure-activity Relationships of Chemokines." J. Leuk. Biol. 57: 703-711, Rucker, J., Doranz, B., Edinger, A., Long, D., Berson, J., and Doms, R. W. "Cell-Cell Fusion Assay to Study Role of Chemokine Receptors in Human Immunodeficiency Virus Type 1 Entry." Methods Enzymol 288: 118-133, 1997. Loetscher, P., Gong, J. H., Dewald, B., Baggiolini, M., and Clark-Lewis, I. "N-Terminal Peptides of Stromal Cell-Derived Factor-1 with CXC Chemokine Receptor 4 Agonist and Antagonist Activities." J. Biol. Chem. 273: 22279-22283, 1998. Heveker, N., Montes, M., Germeroth, L., Amara, A., Trautmann, A., Alizon, M., and Schneider-Mergener, J. "Dissociation of the Signalling and Antiviral Properties of SDF-1 Derived Small Peptides." Current Biology 8: 369-376, 1998. Hèbert, C. A., Vitangcol, R.V., and Baker, J.B. "Scanning Mutagenesis of Interleukin-8 Identifies a e Qe Cluster of Residues Required for Receptor Binding." J. Biol. Chem. 266: 18989-18994, 1991. Crump, M. P., Gong, J. H., Loetscher, P., Rajarathnam, K., Amara, A., Arenzana-Seisdedos, F., ī0 Virelizier, J. L., Baggiolini, M., Sykes, B. D., and Clark-Lewis, I. "Solution Structure and Basis for Functional Activity of Stromal Cell-Derived Factor -1; Dissociation of CXCR4 Activiation from ()lı Binding and Inhibition of HIV-1." EMBO Journal 16: 69996-7007, 1997. Simmons, G., Wilkinson, D., Reeves, J. D., Dittmar, M.T., Beddows, S., Weber, J., Carnegie, G., 11 Desselberger, U., Gray, P. W., Weiss, R. A., and Clapham, P. R. "Primary Syncytium-Inducing Human Immunodeficiency Virus Type 1 Isolates Are Dual-Tropic and Most Can Use Either Lestr or CCR5 as Corecptors for Virus Entry." J. Virol. 70:8355-8360, 1996. Date Considered Examiner

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO - 1449)

Examiner: Emily Le

Date: 5/05/04

^{*} Use publication date indicated on the patent or published application. 37 CFR 1.98(b).

^{**} The place or publication refers to the name of the journal, magazine or other publication in which the article was published. Notice of January 9, 1992, 1135 O.G. 13 to 25 at 20.

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE						ATTY!DOCKET NO. 8321-90			SERIAL NO.: Not Yet Assigned 09/773,830				
INFORMATION DISCLOSURE CITATION													
							APPLICANT: Ziwei Huang, et al						
O 3 Mag						FILING D	DATE F	GROUP Not Yet Assigned					
<u> </u>	PELIFE			l	U.S. PATENT DO	CUMEN	TS				1		
EXAMIN INITIAL			DOCUMENT NUMBER	DATE	МЕ		CLASS	SUBCLASS		FILING DATE (IF APPROPRIATE)			
		AA							ļ				
		—— AВ											
			-	FO]	REIGN PATENT I	OCUM	ENTS						
			DOCUMENT NO.	DATE	COUNT	RY	CLASS SUBC		CLASS TRAN YES		ISLATION NO		
	AC									_			
	AD				DG / Julius Author	Title	Data P	ortinont	Pages	Etc.)		· 	
	AE		Liwang, et al.: '	The Solution	Structure of the Anti-HIV	Chemokine	vMIP-II"	Protein Sc	cience Vo	i. 8, pp.	2270-2280 (1999)	
<u>ve</u>	AF		Cambridge University Press (USA). Learn State of Positively Charged Residues in CXCR4 Recognition Probed with Synthetic Peptides" Biochemical										
<u> </u>	AC		and Biophysical Research Communications Vol. 263, pp. 691-695 (1999) Academic Press (USA) Fernandez, et al.: "Comparison of the Structure of yMIP-II with Eotaxin-1, RANTES, and MCP-3 Suggests a Unique Mechanism for CCR3 Activation" Biochemistry Vol. 39, pp. 12837-12844 (September 26, 2000) American Chemical Society										
elle	AF	I	(USA) Luo, et al.: "Structure-Function Study and Anti-HIV Activity of Synthetic Peptide Analogues Derived form Viral Chemokine Luo, et al.: "Structure-Function Study and Anti-HIV Activity of Synthetic Peptide Analogues Derived form Viral Chemokine Luo, et al.: "Structure-Function Study and Anti-HIV Activity of Synthetic Peptide Analogues Derived form Viral Chemokine										
yy	AI		vMIP-II" Biochemistry Vol. 39, pp. 13343-13330 (October 9, 2006) 7 American and Inhibiting HIV-1 Entry with D-Peptides Zhou, et al.: "Exploring the Stereochemistry of CXCR4-Peptide Recognition and Inhibiting HIV-1 Entry with D-Peptides Derived from Chemokines" The Journal of Biological Chemistry Vol. 277, No. 20, (2002), American Soccity for Biochemistry and Molecular Biology, Inc. (USA)										
EXAM	INER		1			ATE CONS	US/U	4					
Ü	mili	1 0	LL		not citation is in conforman				u ale aleaeir				